Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: Analysis of the literature

Cancer

Volumn 78, Issue 10, 1996, Pages 2127-2135

  Delepine, Nicole ^a   Delepine, Gérard ^b   Bacci, Gaetano ^c   Rosen, Gerald ^d   Desbois, Jean Claude ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

cisplatin; clinical trials; dose intensity; doxorubicin; high dose methotrexate; osteogenic osteosarcoma

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE;

ANALYTIC METHOD; ARTICLE; CANCER GRADING; CANCER SURVIVAL; DATA ANALYSIS; DOSE CALCULATION; DOSE RESPONSE; HUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; REGRESSION ANALYSIS; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; HUMANS; METHOTREXATE; OSTEOSARCOMA; SURVIVAL RATE;

EID: 0029861534     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961115)78:10<2127::AID-CNCR13>3.0.CO;2-0     Document Type: Article

References (48)

1. Dahlin D, Coventry M. Osteogenic sarcoma: a study of six hundred cases. J Bone Joint Surg Am 1967;49:101-10.
2. Burgers JMV. Experience of the EORTC Radiotherapy/Chemotherapy Group in osteosarcoma trials. Cancer Treat Res 1993;62:173-6.
3. Marcove RC, Mike V, Hajek JV, Levin AG, Hutter RVP. Osteogenic sarcoma under the age of twenty-one: a review of one hundred and forty five cases. J Bone Joint Surg Am 1970;52:411-23.
4. McKenna RJ, Schwin CP, Soong KY, Higinbotha NL. Sarcomata of the osteogenic series (osteosarcoma, fibrosarcoma, chondrosarcoma, parostealosteogenic sarcoma and sarcomata arising in abnormal bone): an analysis of 552 cases. J Bone Joint Surg Am 1966;48:1.
5. Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, et al. Primary chemotherapy and delayed surgery for osteosarcoma of the extremities. Cancer 1993;72(11):3227-38.
6. Bramwell VHC, Burgers M, Sneath R, Souhami R, Van Oosterom AT, Voûte PA, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 1992;10:1579-91.
7. Brunat-Mentigny M, Demaille MC, Quintana E, Olive D, Bachelot C, Boitetot A, et al. La reproduction en France du protocole de Rosen pour les ostéosarcomes. Bull Cancer 1988;75:201-6.
8. Kalifa C, Mlika N, Dubousset J, Contesso G, Vanel D, Lumbroso J. Expérience du protocole T10 dans le service de pédiatrie de l'Institut Gustave Roussy. Bull Cancer 1988;75:207-11.
9. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, et al. Chemotherapy for non metastatic osteogenic osteosarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
10. Saeter G, Alvegard TA, Elomaa I, Stenwig AE, Holmström T, Solheim OP. Treatment of osteosarcoma of the extremities with the T 10 protocol, with emphasis on the effect of preoperative chemotherapy with single agent high dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 1991;9:1766-75.
11. Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W. Neoadjuvant chemotherapy of osteosarcoma: results of a cooperative German/Austrian study. J Clin Oncol 1984; 2:617-24.
12. Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfurts C. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS 82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988;6:329-37.
13. Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 1972;30:1627-31.
14. Jaffe N, Paed D, Farber S, Traggis D, Geiser C, Kim BS, et al. Favourable response of metastatic osteogenic sarcoma to high dose methotrexate with citrovorum rescue and radiation therapy. Cancer 1973;31:1367-73.
15. Jaffe N, Frei E III, Traggis D, Watts H. Weekly high dose methotrexate citrovorum factor in osteogenic sarcoma: presurgical treatment of primary tumor and of overt pulmonary metastases. Cancer 1977;39:45-50.
16. Rosen G, Suwansiriku S, Kwon C, Tan C, Wu SJ, Beattie EJ, et al. High dose methotrexate and citrovorum factor rescue and Adriamycin in childhood osteogenic sarcoma. Cancer 1974;33:1151-63.
17. Rosen G, Tan C, Sanmaneechat A, Beattie EJ, Marcove JR, Murphy ML. The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer 1975;35:936-45.
18. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kaloff C, Huvos AG. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979;43:2163-77.
19. Bacci G, Gherlinzoni F, Picci P, Van Horn JR, Jaffe N, Guerra A, et al. Adriamycin-methotrexate high dose versus Adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study. Eur J Cancer Clin Oncol 1986;22:1337-45.
20. Krailo M, Ertel I, Makley J, Fryer CJ, Baum E, Weetman R, et al. A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as component of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the children cancer study group. Med Pediatr Oncol 1987;15:69-77.
21. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. In: Important advances in oncology. Philadelphia: JB Lippincott, 1988:121-41.
22. Levin L, Hryniuk W. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer. Semin Oncol 1987;14:12-9.
23. Van Rijswijk RE, Haanen C, Dekker AW, De Meijer AJ, Verveek J. Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol 1989;7:1776-82.
24. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994;12:423-31.
25. Souhami R, Van der Eijken J, Craft A. A randomized trial of two regimens of chemotherapy in operable osteosarcoma: the second study of the European Osteosarcoma Intergroup. Joint Meeting MSOS-AMSTS, Bologna, Italy, May 14-17, 1995.
26. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse free survival of patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-6.
27. Link MP. The multiinstitutional study: an update. Cancer Treat Res 1993;62:261-7.
28. Miser SJ, Krailo M. The Children's Cancer Group (CCG) studies. Cancer Treat Res 1993;62:254-60.
29. Winkler K, Bielack SS, Delling G, Jürgens H, Kotz R, Salzer-Kuntschik M. Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS). Cancer Treat Res 1993;62:269-77.
30. Goorin AM, Delorey M, Gelber RD, Price K, Vawter G, Jaffe N, et al. Dana Farber Cancer Institute/The Children's Hospital adjuvant chemotherapy trials for osteosarcoma: three sequential studies. Cancer Treat Symp 1985;3:155-9.
31. Goorin AM, Perez-Atayde A, Gebhardt M, Anderson JW, Wilkinson RH, Delorey MJ, et al. Weekly high dose methotrexate and doxorubicin for osteosarcoma: the Dana Farber Cancer Institute/The Children's Hospital Study III. J Clin Oncol 1987;5:1178-84.
32. Rosen G. Preoperative (neoadjuvant) chemotherapy for osteogenic osteosarcoma: a ten years experience. Orthopaedics 1985;8:659-64.
33. Graham-Pole J, Ayass M, Cassano W, Dickson N, Enneking W, Heare M, et al. Neoadjuvant chemotherapy for patients with osteosarcoma: University of Florida studies. Cancer Treat Res 1993;62:339-46.
34. Law LW. Effects of combinations of antileukemic agents on an acute lymphocytic leukemia of mice. Cancer Res 1952; 12:871-8.
35. Chresta CM, Hicks R, Hartley JA, Souhami RL. Potentiation of etoposide-induced cytotoxicities and DNA damage in CCRF-CEM cells by pretreatment with non-cytotoxic concentrations of arabinosyl cytosine. Cancer Chemother Pharmacol 1992;31:139-45.
36. Raude E, Oellerich P, Weinel P, Freund M, Schrappe M, Riehm H, et al. High-dose methotrexate: pharmacokinetics in children and young adults. Int J Clin Pharmacol Ther Toxicol 1988;26:364-70.
37. Huffmann D, Wan S, Azamoff DL, Hoogetraten B. Pharmacokinetics of methotrexate. Clin Pharmacol Ther 1973;14:572-9.
38. Delepine N, Delepine G, Desbois JC, Cornille H, Brun B, Subovici V, et al. Pharmacokinetics of HDMTX: conclusion about 622 courses performed in 4 years in children, teenagers and adults [abstract]. Med Pediatr Oncol 1989;17(4):304.
39. Delepine N, Delepine G, Comille H, Desbois JC, Misset JL High value of pharmacokinetics adaptation in success of treatment of osteosarcoma by protocols based on high dose methotrexate [abstract 1240]. Proc Am Soc Clin Oncol 1989;8:319.
40. Ferrari S, Sassoli V, Orlandi M, Strazzari S, Puggioli C, Battistini A, et al. Serum methotrexate and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. J Chemother 1993;5(2):135-41.
41. Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994;12:1443-51.
42. Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic osteosarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991;83:1460-70.
43. Blaney SM, Smith MA, Grem JL. Doxorubicin: role in the treatment of osteosarcoma. Cancer Treat Res 1993;62:55-73.
44. Goorin AM, Chauvenet AR, Perez-Atayade AR, Cruz J, McKone R, Lipshulz SE. Initial congestive heart failure six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 1990;116:144-7
45. Bacci G, Picci P, Ferrari S, Casadei R, Brach del Prever A, Tienghi A, et al. Influence of Adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: results of two sequential studies. J Chemother 1993;5(4):237-46.
46. Rosen G, Nirenberg A. Chemotherapy for osteogenic sarcoma: an investigative method, not a recipe. Cancer Treat Rep 1982;66:1687-97.
47. Delépine N, Delepine G, Cornille H, Brion F, Arnaud P, Desbois JC. Dose escalation with pharmacokinetics monitoring in methotrexate therapy of osteosarcoma. Anticancer Res 1995;15:489-94.
48. Delépine N, Delepine G, Desbois JC. A monocentric therapy study: an approach to optimize the results of the treatment of osteosarcoma by protocols based upon HDMTX, associated with systematic conservative surgery. Cancer Treat Res 1993;62:327-32.